Personalized Medicine in Oncology Drug Development

作者
Nicholas C. Dracopoli,Iqbal S. Grewal,Chris H. Takimoto,Peter F. Lebowitz
标识
DOI:10.1002/9781119000822.hfcm052
摘要

Overview The concept of personalized medicine in oncology drug development is no longer an aspiration; it is now, in large measure, the accepted paradigm of how oncology drugs should be developed. In modern oncology drug development, determining which molecularly characterized tumors will benefit the most from a drug is a critical part of the development plan. In addition, another important personalized medicine approach is emerging whereby a therapeutic is specific to an individual patient. Examples of this individualized therapeutic approach include engineering of autologous immune cells with reinfusion into the patient or cancer vaccines that are specific to an individual tumor. A growing number of successful examples have demonstrated that the personalized medicine approach via biomarker selection can provide more benefit to patients and more rapid approval of drugs. The benefits of a personalized medicine strategy in oncology drug development are multiple and include an increased probability of overall success, smaller Phase 3 registration trials, and the potential for enhanced clinical benefits for patients. In a recent review, Falconi and colleagues examined the outcome of 676 Phase 1, 2, and 3 clinical trials of novel therapeutics for non‐small cell lung cancer conducted from 1998 to 2012. 1 Overall, the cumulative success rate, as defined by the advancement to the next stage of clinical testing or to approval, was only 11%. However, when a biomarker was utilized for patient selection, the cumulative success rate increased by nearly sixfold to 62%. Thus, there is strong objective evidence for predictive biomarkers to enhance the probability of success in drug development. Using specific genetic and/or protein markers, a number of important drugs have been developed and approved in specific populations. This approach represents a paradigm shift that has proved so powerful that it is now a standard.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shuyiWang发布了新的文献求助10
1秒前
wuwu发布了新的文献求助10
1秒前
sy关注了科研通微信公众号
2秒前
2秒前
隐形曼青的应助被嘟嘟采纳,获得10
3秒前
思源的应助被晨辰采纳,获得10
4秒前
WBLJ完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
6秒前
joule完成签到,获得积分10
6秒前
江江完成签到,获得积分10
7秒前
7秒前
7秒前
Ava的应助被dyq采纳,获得10
8秒前
成就煎饼发布了新的文献求助10
8秒前
qys发布了新的文献求助10
8秒前
8秒前
9秒前
10秒前
MSY完成签到 ,获得积分10
10秒前
小二郎的应助被干饭啦采纳,获得10
10秒前
奶茶电竞精神完成签到 ,获得积分10
10秒前
空白发布了新的文献求助30
11秒前
大个的应助被叶素绿采纳,获得10
12秒前
12秒前
余香的应助被jzt12138采纳,获得10
13秒前
木子发布了新的文献求助10
14秒前
14秒前
GFY发布了新的文献求助10
14秒前
14秒前
fanfan发布了新的文献求助10
15秒前
华仔的应助被谨慎的秋烟采纳,获得10
15秒前
17秒前
zaka完成签到,获得积分20
18秒前
sun完成签到,获得积分10
19秒前
19秒前
小朋友发布了新的文献求助10
20秒前
大橙子发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163746
求助须知:如何正确求助?哪些是违规求助? 9557874
关于积分的说明 21742203
捐赠科研通 7754407
什么是DOI,文献DOI怎么找? 3428345
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472945